Published in TB and Outbreaks Week, August 16th, 2005
Study 1: Researchers review recent advances in production technologies for influenza vaccines in a recent issue of Applied Microbiology and Biotechnology.
"In spite of ongoing annual vaccination programs, the seasonal influenza epidemics remain a major cause of high morbidity and mortality. The currently used 'inactivated' vaccines provide very short-term and highly specific humoral immunity due to the frequent antigenic variations in the influenza virion. These intramuscularly administered vaccines also fail to induce protective mucosal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.